Status | Study |
Completed |
Study Name: OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Condition: Chonic Spontaneous Urticaria Date: 2014-06-10 Interventions: Drug: omalizumab 150mg omalizu |
Completed |
Study Name: Hereditary AngioEdema, Neurobiology and Psychopathology Condition: Hereditary AngioEdema Anxiety Date: 2014-06-05 Interventions: Other: Clinical and psychopathological assessment of HAE patients |
Completed |
Study Name: A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 Condition: Hereditary Angioedema Date: 2014-04-24 Interventions: Drug: BCX4161 Each subject will receive Treatments A, B, and C in an open-label, randomized sequence wit |
Completed |
Study Name: Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects Condition: Hereditary Angioedema Date: 2014-03-17 Interventions: Drug: DX-2930 DX-2930 is a rec |
Completed |
Study Name: Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Condition: Hereditary Angioedema (HAE) Date: 2014-01-30 Interventions: Biological: CINRYZE 500 500 Un |
Completed |
Study Name: Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers Condition: Hereditary Angioedema (HAE) Date: 2014-01-13 Interventions: Drug: Icatibant (30 mg) On Day 1, subjects will receive a single 30mg subcutaneous injection of icatiban |
Completed |
Study Name: Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE Condition: Hereditary Angioedema Date: 2013-11-05 Interventions: Drug: BCX4161 Drug: Placebo |
Completed |
Study Name: A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects Condition: Hereditary Angioedema (HAE) Date: 2013-08-08 Interventions: Drug: DX-2930 Drug: Placebo |
Completed |
Study Name: A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Condition: Hereditary Angioedema Types I and II Date: 2013-07-29 Interventions: Biological: Low-volume C1-esterase inhibitor |
Completed |
Study Name: Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Condition: Angiotensin Converting Enzyme Inhibitor Induced Angioedema Date: 2013-07-25 Interventions: Drug: Icatibant Single dose of |